Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Therapeutic Advances in Gastroenterology
|
September 22, 2017
Clinical performance of an infliximab rapid quantification assay
Fernando Magro, Joana Afonso, Susana Lopes, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 4, 2018
Metabolic control of T cell immune response through glycans in inflammatory bowel disease
Ana M Dias, Alexandra Correia, Márcia S Pereira, et al.
Journal of Crohn'S & Colitis
|
August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on Infliximab
Fernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
Fernando Magro, Diogo Magalhães, Marta Patita, et al.
Journal of Crohn'S & Colitis
|
January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
Fernando Magro, Samuel Fernandes, Marta Patita, et al.
Ebiomedicine
|
June 21, 2017
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
Fernando Magro, Joana Afonso, Susana Lopes, et al.
United European Gastroenterology Journal
|
June 15, 2023
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study
Fernando Magro, Maria Manuela Estevinho, Gaia Catalano, et al.
Therapeutic Advances in Gastroenterology
|
November 3, 2016
Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays
Joana Afonso, Susana Lopes, Raquel Gonçalves, et al.
Inflammatory Bowel Diseases
|
May 11, 2012
Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II)
Cecília Durães, José C Machado, Francisco Portela, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 13, 2020
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Fernando Magro, Catarina Alves, Joanne Lopes, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Therapeutic Advances in Gastroenterology
|
September 22, 2017
Clinical performance of an infliximab rapid quantification assay
Fernando Magro, Joana Afonso, Susana Lopes, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 4, 2018
Metabolic control of T cell immune response through glycans in inflammatory bowel disease
Ana M Dias, Alexandra Correia, Márcia S Pereira, et al.
Journal of Crohn'S & Colitis
|
August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on Infliximab
Fernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
Fernando Magro, Diogo Magalhães, Marta Patita, et al.
Journal of Crohn'S & Colitis
|
January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
Fernando Magro, Samuel Fernandes, Marta Patita, et al.
Ebiomedicine
|
June 21, 2017
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
Fernando Magro, Joana Afonso, Susana Lopes, et al.
United European Gastroenterology Journal
|
June 15, 2023
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study
Fernando Magro, Maria Manuela Estevinho, Gaia Catalano, et al.
Therapeutic Advances in Gastroenterology
|
November 3, 2016
Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays
Joana Afonso, Susana Lopes, Raquel Gonçalves, et al.
Inflammatory Bowel Diseases
|
May 11, 2012
Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II)
Cecília Durães, José C Machado, Francisco Portela, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 13, 2020
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Fernando Magro, Catarina Alves, Joanne Lopes, et al.
Page
of 9